Back to top
more

Henry Schein (HSIC)

(Real Time Quote from BATS)

$73.23 USD

73.23
412,692

-0.24 (-0.33%)

Updated May 21, 2024 02:59 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 34% (164 out of 248)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Henry Schein (HSIC) Tops Q2 Earnings and Revenues Estimate

by Zacks Equity Research

Henry Schein (HSIC) rides high on all four segments in Q2 delivered solid earnings growth on back of the strategy to grow the business organically and through acquisitions.

    Med-Product Stocks Aug 8 Earnings Roster: HSIC, AGIO & More

    by Zacks Equity Research

    Long-term tailwinds including M&A, emerging markets, positive demographic trends and new product innovation might bode well for the medical device industry.

      Can Henry Schein (HSIC) Spring a Surprise in Q2 Earnings?

      by Zacks Equity Research

      The timing of Good Friday is likely to dampen sales at Henry Schein (HSIC) in second-quarter 2017. Meanwhile, geographic expansion should continue.

        Here's Why Henry Schein is Worth Adding to Your Portfolio

        by Zacks Equity Research

        Over the last six months, Henry Schein Inc. (HSIC) was consistently trading ahead of the S&P 500 Index.

          Henry Schein Grows on Strategic Buyouts, Competition Rife

          by Zacks Equity Research

          On Jun 15, we issued an updated research report on Melville, NY-based Henry Schein, Inc. (HSIC).

            Henry Schein (HSIC) Up 5.3% Since Earnings Report: Can It Continue?

            by Zacks Equity Research

            Henry Schein (HSIC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

              Henry Schein (HSIC) Rides on Global Growth, Strategic Deals

              by Zacks Equity Research

              On May 25 2017, we issued an updated research report on Melville, NY-based Henry Schein, Inc. (HSIC).

                Pure Storage (PSTG) Posts Narrower-than-Expected Q1 Loss

                by Zacks Equity Research

                Pure Storage Inc. (PSTG) reported non-GAAP loss (including stock-based compensation) of 30 cents per share in the first-quarter of fiscal 2018, which was narrower than the Zacks Consensus Estimate by 8 cents.

                  Henry Schein (HSIC) Tops Q1 Earnings, Reaffirms '17 View

                  by Zacks Equity Research

                  Henry Schein, Inc. (HSIC) reported adjusted earnings per share (EPS) of $1.76 in the first quarter of 2017, up 24.8% year over year.

                    Henry Schein (HSIC) Tops Q1 Earnings and Revenues Estimate

                    by Zacks Equity Research

                    Headquartered in Melville, NY, Henry Schein Inc. (HSIC) is a global leading provider of healthcare products and services.

                      Medical Product Q1 Earnings Due on May 9: XRAY, HSIC & More

                      by Zacks Equity Research

                      Medical product, an important part of the medical device subcategory within the broader Medical sector, looks promising at the moment.

                        Will Henry Schein (HSIC) Deliver a Surprise in Q1 Earnings?

                        by Zacks Equity Research

                        Henry Schein, Inc. (HSIC) is expected to report first-quarter 2017 results on May 2, before the opening bell.

                          Henry Schein (HSIC) Poised on Solid Growth, Risks Remain

                          by Zacks Equity Research

                          On Mar 27, we issued an updated research report on Melville, NY-based Henry Schein, Inc. (HSIC).

                            Henry Schein Inks Agreement for Rijuven's CardioSleeve

                            by Zacks Equity Research

                            Henry Schein, Inc. (HSIC) recently signed an exclusive distribution agreement with patient care platform designer Rijuven Corp. to sell the latter's CardioSleeve device

                              Henry Schein (HSIC) Tops Q4 Earnings, Reaffirms '17 View

                              by Zacks Equity Research

                              Henry Schein, Inc. (HSIC) reported adjusted earnings per share of $1.88 in the fourth quarter of 2016, up 12.6% year over year and surpassed the Zacks Consensus Estimate by 2.2%.

                                Henry Schein (HSIC) Tops Q4 Earnings and Revenues Estimates

                                by Zacks Equity Research

                                Henry Schein (HSIC) reported positive fourth quarter 2016 results with earnings and sales exceeding the Zacks Consensus Estimate.

                                  Henry Schein to Acquire SAS to Strengthen Dental Offerings

                                  by Zacks Equity Research

                                  Henry Schein Inc. (HSIC) announced its decision to acquire Southern Anesthesia + Surgical (SAS).

                                    MedTech Stocks Earnings Slated on Feb 21: MDT, HSIC and More

                                    by Zacks Equity Research

                                    Let's take a look at the major MedTech stocks slated to release their Oct-Dec 2016 numbers on Feb 21.

                                      Henry Schein (HSIC) Q4 Earnings: Disappointment in Store?

                                      by Zacks Equity Research

                                      Henry Schein, Inc. (HSIC) is expected to report fourth-quarter 2016 financial numbers on Feb 8, before the opening bell.

                                        Henry Schein Hurt by Higher Costs, Lacks Growth Drivers

                                        by Zacks Equity Research

                                        On Jan 10, we issued an updated research report on Melville, NY-based Henry Schein, Inc. (HSIC).

                                          Henry Schein Named 2016's Best Animal Healthcare Provider

                                          by Zacks Equity Research

                                          Henry Schein, Inc. (HSIC) has been recognized as the "Best Animal Healthcare Product Provider 2016".

                                            Henry Schein Buys Stake in Marrodent; Spurs Polish Foothold

                                            by Zacks Equity Research

                                            Henry Schein (HSIC) has recently completed its earlier announced purchase of 80% ownership of Marrodent.

                                              Henry Schein's Q3 Results Impress, Pricing Pressure a Drag

                                              by Zacks Equity Research

                                              On Dec 6, we issued an updated research report on Melville, NY-based Henry Schein Inc. (HSIC).